We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral Anticoagulant Use in a Racial and Ethnically Diverse Population with Atrial Fibrillation.
- Authors
Srivastava, Ankur; Sun, Eric; Hasani, Aliasakar; Fisher, John D.; Ferrick, Kevin J.; Krumerman, Andrew K.
- Abstract
Patients older than 18 were included if they were prescribed anticoagulation, as per the 2019 ACC-AHA-HRS guidelines, with warfarin, apixaban, rivaroxaban, edoxaban, or dabigatran.[1] Patients with valvular atrial fibrillation and stroke within 1 month of diagnosis were excluded. INTRODUCTION Warfarin is an established therapy to prevent ischemic stroke in patients with atrial fibrillation.[1] Direct oral anticoagulants (DOACs) have emerged as alternative therapies due to favorable risk-benefit profiles compared with warfarin.[1] Many patients with atrial fibrillation that meet guideline recommended criteria, especially Black and Hispanic patients, are not treated with anticoagulants.[2] Several investigators have noted differences in oral anticoagulant treatment for atrial fibrillation in Black and Hispanic patients compared with their white counterparts.[2], [3] However, a major shortcoming of these studies is the limited representation of patients of color. It runs counter to findings of other investigators that demonstrated less frequent use of DOACs in patients of minority backgrounds as compared with white patients.[2]-[4] In a study by Bhave et al., anticoagulant use was investigated in a population of 517,941 patients, comprised of 87% white patients, in which Black and Hispanic patients were less likely to receive oral anticoagulants.[2] In contrast, patients of color made up more than half of our patient cohort.
- Subjects
ATRIAL fibrillation; STROKE; ANTICOAGULANTS; TRANSIENT ischemic attack; PERIPHERAL vascular diseases
- Publication
JGIM: Journal of General Internal Medicine, 2021, Vol 36, Issue 9, p2877
- ISSN
0884-8734
- Publication type
Letter
- DOI
10.1007/s11606-020-06184-4